Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
ResMed logo

ResMed Cash Flow Statement

Operating, investing, and financing cash movements

Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$1.9BNet Cash From Investing (TTM)-$295.3MNet Cash From Financing (TTM)-$907.8MCapital Expenditures (TTM)$135.7MDepreciation And Amortization Cf (TTM)$220.2MNet Change In Cash (TTM)$727.8M
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$27.9B
P/E Ratio18.41
ROE25.19%

Investing

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Acquisitions, net of cash acquired$670K$0$138.6M$522K—$24.9M
Capital expenditures$20.6M$20.8M$30.6M$43M$28.5M$33.7M
Payment For Patent Registration And Acquisition Costs—$3M———$5.9M
Payments for (Proceeds from) Derivative Instrument, Investing Activities——-$40.4M$4.1M$12.4M-$24.1M
Payments To Acquire Businesses Gross$670K$0$138.6M$522K—$24.9M
Payments to Acquire Intangible Assets-$1.8M$0$10.8M$2.8M——
Proceeds from disposition of marketable securities and other investments$250K$0$250K$0$250K$2.5M
Net cash from investing activities-$36.7M-$31.8M-$133.7M-$52.6M-$50.9M-$58M
Proceeds from maturities/sales of investments$250K$0$250K$0$250K$2.5M
Purchases of intangible assets-$1.8M$0$10.8M$2.8M——
Purchases of investments$1M$2.1M$2M$2.2M$4.2M$20.1M

Operating

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Change in accounts payable$4.2M$63.1M$49.1M$7.6M$10.6M$103.9M
Change in accounts receivable$67.9M$40M$5.2M-$30M$72.7M$16.9M
Change in inventories$7.6M—$32.1M$14.7M-$26.1M-$12.5M
Change in other assets$43.6M-$79.4M-$47M-$2.3M$106.4M$48.3M
Depreciation and amortization$46.4M$43.7M$63.6M$47.7M$49.9M$59M
Distributions from equity method investments$911K$911K$911K———
Net gains (losses) on investments-$1.4M-$5.6M-$2.5M-$6.2M—-$10.1M
Net cash from operating activities$308.6M$578.7M$538.8M$457.3M$339.7M$554.1M
Net income$344.6M$365M$379.7M$348.5M$392.6M$398.7M
Unrealized gain (loss) on debt and equity securities, net-$1.4M-$5.6M-$2.5M-$6.2M—-$10.1M
Equity in earnings (losses) of equity method investees$1.1M$335K$1.3M$1.5M$1.5M$1.7M
Income Loss From Equity Method Investments Net Of Dividends Or Distributions$911K$911K$911K———
Increase (Decrease) in Prepaid Expense and Other Assets$43.6M-$79.4M-$47M-$2.3M$106.4M$48.3M
Insurance Recoveries$0$0$0———
Non-cash operating lease expense$9.5M$8.2M$10.7M$10M$12.4M$10.1M
Operating lease right-of-use asset amortization$9.5M$8.2M$10.7M$10M$12.4M$10.1M
Stock-based compensation$22.6M$24.1M$24.8M$21.2M$28.9M$26.8M

Financing

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Repayments of debt$5M$0$5M$0$5M—
Dividends paid$77.7M$77.7M$77.6M$87.8M$87.6M$87.2M
Acquisition Of Consolidated Subsidiary, Financing Activities$2.7M$2.7M$2.7M———
Net cash from financing activities-$147.5M-$144.1M-$163.9M-$230.3M-$258.3M-$255.2M
Proceeds from issuance of common stock$26.9M$9M$30.2M$8.2M$29.6M$7.4M
Repurchases of common stock$75M$75M$100M$150M$175M$175M
Taxes paid for net share settlement$16.7M$364K$590K$719K$20.3M$418K

Free Cash Flow

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Free cash flow$288M$557.9M$508.2M$414.4M$311.2M$520.5M

Other

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Effect of exchange rate changes on cash-$28.8M$8M$35.6M-$71K$2.8M$2.6M
Net increase (decrease) in cash$95.6M$410.8M$276.7M$174.4M$33.2M$243.4M
Payments Of Merger Related Costs Financing Activities———$0$0$0
Restructuring Reserve Settled Without Cash2$0$0$0———

Supplemental

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Income taxes paid$118.6M—$16.2M$61.9M$147.5M$71.7M
Interest paid$0$14.2M$6.9M$6.9M$6.6M$6.5M
Business Acquisition, Contingent Consideration, Recognized Liability$670K——$0$0-$3.2M
Deferred payments$0$0$670K———
Goodwill on acquisition$0$0$101.3M$1.3M—$18.9M
Income Taxes Paid, Net$118.6M—$16.2M$61.9M$147.5M$71.7M
Fair value of assets acquired, excluding cash$0$0$43.5M-$798K—$15.6M